MAPT and Alzheimer disease: Interestingly, van Eersel et al. (2010) and Jin et al. (2017) used transgenic animal models of AD to show that sodium selenate reduced tau protein phosphorylation and ameliorated cognitive impairment in AD mice by regulating the activity of protein phosphatase 2A (PP2A) (Ishrat et al., 2009; Lovell et al., 2009; Corcoran et al., 2010; van Eersel et al., 2010; Jin et al., 2017), which undoubtedly promoted research regarding Se in AD prevention and treatment.